Figure 1
From: Ebselen analogues delay disease onset and its course in fALS by on-target SOD-1 engagement
Cell viability of human and mouse neuronal cells expressing wild-type SOD1 and ALS-associated mutants of A4V and G93A under treatments of ebselen-based compounds and ALS-approved drugs. (A) Chemical structures of approved ALS drugs, ebselen and derivatives. (B) MTS assay of mouse N2a neuroblastoma cells transfected with G93A SOD1. (C) human H4 neuroglioma cells transfected with A4V SOD1, and (D,E) ATP bioluminescent assay for single compound and in combination with approved drugs using human H4 neuroglioma cells transfected with wild-type, A4V and G93A SOD1. Cell viability levels are shown in bar chart with data points and error bars representing standard deviation of the mean from at least 6 separate measurements. Asterisks above bar charts indicate statistically significant improvements (p < 0.05) against untreated control groups.
